IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells.
Saved in:
| Title: | IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. |
|---|---|
| Authors: | Kehl N; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Kilian M; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Michel J; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Wagner TR; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; GMP and Cell Therapy Group, German Cancer Research Center (DKFZ), Heidelberg, Germany., Uhrig S; Molecular Precision Oncology Program, National Center for Tumor Diseases, Heidelberg, Germany., Brobeil A; Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Sester LS; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Blobner S; Department of Translational Oncology, National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany., Steiger S; Division of Chromatin Networks, BioQuant Center and German Cancer Research Center (DKFZ), Heidelberg, Germany., Hundemer M; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Weinhold N; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Rippe K; Division of Chromatin Networks, BioQuant Center and German Cancer Research Center (DKFZ), Heidelberg, Germany., Fröhling S; Department of Translational Oncology, National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany., Eichmüller SB; GMP and Cell Therapy Group, German Cancer Research Center (DKFZ), Heidelberg, Germany., Bunse L; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Goldschmidt H; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany., Platten M; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.; National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany.; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany., Raab MS; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology / Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Friedrich MJ; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany mirco.friedrich@dkfz.de.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Oct; Vol. 10 (10). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
